MMUNOGLOBULIN, BISPECIFIC TETRAVALENT, ANTI-(HUMAN CD3 ANTIGEN) (HUMAN MONOCLONAL AMV564 .KAPPA.-CHAIN VL1) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC LINKER1) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD33 ANTIGEN) (HUMAN MONOCLONAL AMV564 SINGLE-CHAIN VARIABLE FRAGMENT VH2-LINKER2-VL2) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC LINKER1) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN) (HUMAN MONOCLONAL AMV564 HEAVY CHAIN VH1)
Locally Advanced or Metastatic Solid Tumors
Amphivena Therapeutics, Inc.monoclonal_antibodyPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
36 Active assets in the Locally Advanced or Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atezolizumab Genentech, Inc. | Phase 2 | B |
gh21 Suzhou Genhouse Bio Co., Ltd. | Phase 2 | CCC |
Pembrolizumab Biocity Biopharmaceutics Co., Ltd. | Phase 1/2 | CCC |
Garsorasib Suzhou Genhouse Bio Co., Ltd. | Phase 2 | CCC |
cvl237 tablets Convalife (Shanghai) Co., Ltd. | Phase 2 | CCC |
View all 46 →
Same molecule, other indications
MMUNOGLOBULIN, BISPECIFIC TETRAVALENT, ANTI-(HUMAN CD3 ANTIGEN) (HUMAN MONOCLONAL AMV564 .KAPPA.-CHAIN VL1) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC LINKER1) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD33 ANTIGEN) (HUMAN MONOCLONAL AMV564 SINGLE-CHAIN VARIABLE FRAGMENT VH2-LINKER2-VL2) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC LINKER1) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN) (HUMAN MONOCLONAL AMV564 HEAVY CHAIN VH1) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →